Revolutionary therapies for IBD and Celiac disease are achievable.
We are rethinking the approach to inflammatory bowel disease and Celiac disease by targeting novel, non-immunosuppressive pathways.
We are rethinking the approach to IBD and Celiac by targeting novel, non-immunosuppressive pathways.
Research Focus
Multiple Pathways
We are leveraging cutting edge scientific research to target pathways that affect multiple known mechanisms implicated in IBD and Celiac disease.
Learn more
Tissue Targeted Delivery
Getting the right dose of the right drug to the right place at the right time is the key to effective treatment. We are exploring novel delivery methods to achieve this.
Learn more
Immune Modulation
Rather than aggressively suppressing the immune system, we are exploring ways to modulate the immune system to restore homeostasis.
Learn moreOur Mission
We are the first and only mission-driven biotech developing targeted immune modulators to treat chronic inflammatory diseases with high unmet needs. We recognize the unmet needs because we are patients and family members of patients.
These diseases affect a large patient population, are often diagnosed in the first decades of life, and currently have a chronic and high disease burden. We have hit a (low) therapeutic ceiling in the biologics era where, unfortunately, the majority of patients are failed by existing medications, develop antibodies, or have intolerable side effects. We need to do better and we can.
Our goal is to create lead assets with extensive proof-of-concept basic science, preclinical, toxicologic, and clinical data while also providing an opportunity to be first and best-in class with an oral, tissue-targeted, non-immunosuppressive therapy to improve the lives of patients.
